This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HealthEquity (HQY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 8.57% and 4.60%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
PINC vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -25.53% and 23.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PINC or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
PINC vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare
by Zacks Equity Research
HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.
3 Medical Services Stocks Braving Near-Term Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.
HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.
HealthEquity (HQY) Misses Q2 Earnings Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Premier, Inc. (PINC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.67% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
XpresSpa Group, Inc. (XSPA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 20% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ICLR vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. HQY: Which Stock Is the Better Value Option?
Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Why Is HealthEquity (HQY) Down 10% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.